{"id":7122,"date":"2025-11-11T08:00:00","date_gmt":"2025-11-11T13:00:00","guid":{"rendered":"https:\/\/cqdm.org\/?p=7122"},"modified":"2025-11-11T08:10:24","modified_gmt":"2025-11-11T13:10:24","slug":"new-collaboration-between-saguaro-biosciences-and-a-leading-global-pharmaceutical-company-to-enhance-drug-discovery-with-live-cell-painting-technology","status":"publish","type":"post","link":"https:\/\/cqdm.org\/en\/news-and-events\/new-collaboration-between-saguaro-biosciences-and-a-leading-global-pharmaceutical-company-to-enhance-drug-discovery-with-live-cell-painting-technology\/","title":{"rendered":"New Collaboration Between Saguaro Biosciences and A Leading Global Pharmaceutical Company to Enhance Drug Discovery With Live Cell Painting Technology"},"content":{"rendered":"\n<p class=\"has-text-align-center\"><strong>&#8212; Project funded through CQDM Quantum Leap program &#8212;<\/strong><\/p>\n\n\n\n<p><\/p>\n\n\n\n<p><strong>Montr\u00e9al, QU\u00c9BEC, November 11, 2025<\/strong> \u2013 CQDM and Saguaro Biosciences are proud to announce that the company has received more than $780,000 to further enhance ChromaLIVE<sup>TM<\/sup>, the leading image-based profiling technology for AI-enabled drug discovery. ChromaLIVE<sup>TM<\/sup> is a non-toxic and multichromatic dye that allows the generation of data-rich images of live cells at large scale and capture time-sensitive biological insights for an improved assessment of drug efficacy and safety. The two-year project is funded through the CQDM Quantum Leap program, which supports exploration of innovative technologies, tools, and platforms that accelerate or facilitate drug discovery and development. A leading global pharmaceutical company is supporting the project as a member of CQDM.<\/p>\n\n\n\n<p><em>\u201cWe are proud to have the strategic support of a global leader for this CQDM Quantum Leap project\u201d <\/em>said Louis Turcotte, CEO and Co-founder of Saguaro.<em> \u201cIt allows us to significantly enhance ChromaLIVE\u2122 and create unparalleled datasets, pushing the boundaries of live-cell screening for AI-enabled drug discovery.\u201d<\/em><\/p>\n\n\n\n<p>As part of this CQDM project, researchers at Saguaro will push the boundaries of its proprietary dye technology in order to further enhance phenotypic resolution, while keeping its non-perturbing properties it is already recognized for. The project will also serve to create the world\u2019s largest live cell image-based based profiling database, which will incorporate the most high-quality biological data through the probing of cells in their native, and unperturbed live state. This dataset will also incorporate the temporal dimension to shine new light on drug\u2019s time-sensitive mechanisms of action that cannot be investigated with end-point assays.<\/p>\n\n\n\n<p><em>\u201cBy further enhancing ChromaLIVE\u2122 and enabling the capture of critical, time-sensitive biological insights, we are fostering the generation of new high-quality datasets the industry needs to significantly improve drug assessment\u201d<\/em>, said F\u00e9lix Lavoie-P\u00e9russe, CCO and Co-Founder of Saguaro.<\/p>\n\n\n\n<p>Jesse Paterson, CQDM Senior Director of Business Development, added:<em> \u201cCQDM is proud to support the development of a cutting-edge research tool with the potential to significantly accelerate drug discovery. This project reflects the power of connecting Canadian expertise with leading global pharmaceutical partners, and we are pleased to play a role in fostering this collaboration through our Quantum Leap program.\u201d<\/em><\/p>\n\n\n\n<p><\/p>\n\n\n\n<p><\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity is-style-dots\"\/>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>About CQDM<\/strong><\/h3>\n\n\n\n<p><em>Biopharma Innovation Facilitator<\/em>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<br>CQDM is a not-for-profit biopharmaceutical research consortium whose mission is to support and facilitate collaborative multi-stakeholder research and development aimed at accelerating the translation or transformation of innovative technologies into solutions to unmet medical needs, while generating significant benefits for the Quebec and Canadian economy. For more information, consult our website&nbsp; <a href=\"https:\/\/cqdm.org\/en\/\">cqdm.org\/<\/a> and join us on <a href=\"https:\/\/www.linkedin.com\/company\/cqdm\/\" target=\"_blank\" rel=\"noopener\">LinkedIn.<\/a><\/p>\n\n\n\n<p><strong>Contacts:<\/strong><br>Jesse Paterson<br>CQDM Senior Director, Business Development<br>+1 (514) 850-7088<br><a href=\"mailto:jpaterson@cqdm.org\">jpaterson@cqdm.org<\/a><\/p>\n\n\n\n<p><\/p>\n\n\n\n<p><\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>About Saguaro Bio<\/strong><\/h3>\n\n\n\n<p>Saguaro Biosciences is dedicated to advancing life sciences with innovative reagents for AI-enabled cell analysis. With its flagship product, ChromaLive<sup>TM<\/sup>, the company provides researchers around the world with powerful tools to demystify cell biology, thereby accelerating the path to new discoveries and therapies. For more information, visit <a href=\"http:\/\/www.saguarobio.com\" target=\"_blank\" rel=\"noopener\">www.saguarobio.com<\/a> and connect with us on <a href=\"https:\/\/www.linkedin.com\/company\/saguarobio\/\" target=\"_blank\" rel=\"noopener\">Linkedin<\/a>.<\/p>\n\n\n\n<p><strong>Contacts:<\/strong><br>Louis Turcotte<br>Chief Executive Officer<br><a href=\"mailto:lturcotte@saguarobio.com\">lturcotte@saguarobio.com<\/a><\/p>\n\n\n\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>&#8212; Project funded through CQDM Quantum Leap program &#8212; Montr\u00e9al, QU\u00c9BEC, November 11, 2025 \u2013 CQDM and Saguaro Biosciences are proud to announce that the company has received more than $780,000 to further enhance ChromaLIVETM, the leading image-based profiling technology for AI-enabled drug discovery. ChromaLIVETM is a non-toxic and multichromatic dye that allows the generation&hellip;<\/p>\n","protected":false},"author":2,"featured_media":7120,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[1],"tags":[],"class_list":["post-7122","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-our-news"],"acf":[],"_links":{"self":[{"href":"https:\/\/cqdm.org\/en\/wp-json\/wp\/v2\/posts\/7122","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cqdm.org\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cqdm.org\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cqdm.org\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/cqdm.org\/en\/wp-json\/wp\/v2\/comments?post=7122"}],"version-history":[{"count":4,"href":"https:\/\/cqdm.org\/en\/wp-json\/wp\/v2\/posts\/7122\/revisions"}],"predecessor-version":[{"id":7142,"href":"https:\/\/cqdm.org\/en\/wp-json\/wp\/v2\/posts\/7122\/revisions\/7142"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cqdm.org\/en\/wp-json\/wp\/v2\/media\/7120"}],"wp:attachment":[{"href":"https:\/\/cqdm.org\/en\/wp-json\/wp\/v2\/media?parent=7122"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cqdm.org\/en\/wp-json\/wp\/v2\/categories?post=7122"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cqdm.org\/en\/wp-json\/wp\/v2\/tags?post=7122"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}